Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. HIMS
HIMS logo

HIMS Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
35.600
Open
32.600
VWAP
34.55
Vol
31.90M
Mkt Cap
8.21B
Low
32.590
Amount
1.10B
EV/EBITDA(TTM)
72.97
Total Shares
231.46M
EV
8.43B
EV/OCF(TTM)
30.09
P/S(TTM)
3.74
Hims & Hers Health, Inc. operates as a consumer-first platform, which helps customers to fulfill their health and wellness needs. Its platform includes access to a provider network, a clinically focused electronic medical record system, digital prescriptions, cloud-enabled pharmacy fulfillment, and personalization capabilities. Its digital platform enables access to treatments for a range of conditions, including primarily those related to sexual health, hair loss, hormone health, weight loss, dermatology, and mental health, as well as services such as comprehensive laboratory testing. It connects patients to licensed healthcare professionals who can prescribe medications when appropriate and prescriptions are fulfilled online through licensed pharmacies. It also offers access to a range of health and wellness products designed to meet individual needs, which can include curated prescription and non-prescription products.
Show More

Events Timeline

(ET)
2026-06-18
17:00:00
Hims and Hers Health Shares Rise 11.49%
select
2026-06-15 (ET)
2026-06-15
15:00:00
Hims and Hers Health Shares Rise 10.7%
select
2026-06-04 (ET)
2026-06-04
09:10:00
Hims & Hers Health Appoints Anant Vinjamoori as Chief Medical Officer
select
2026-05-28 (ET)
2026-05-28
12:20:00
Hims & Hers Health Expands Benefits Program with Eight New Partners
select

News

stocktwits
2.0
05:10 AMstocktwits
HIMS CMO Plans to Sell Shares Amid Positive Market Trends
  • Share Sale Plan: Chief Medical Officer Patrick Carroll filed to sell 23,726 shares worth approximately $830,000, which may impact short-term market confidence in HIMS, despite the stock rising 36% in June.
  • Wearable Integration: CEO Andrew Dudum announced that the integration of Oura Ring is coming soon, indicating a strategic push for HIMS in wearable connectivity aimed at enhancing user experience and medical service capabilities on the platform.
  • Wall Street Optimism: Barclays raised HIMS's price target from $29 to $39, anticipating significant revenue and EBITDA acceleration in the second half of 2026, reflecting increased market confidence in the company's future growth.
  • Positive Market Sentiment: On Stocktwits, retail sentiment for HIMS was bullish, with a 388% surge in message volume over 24 hours, indicating investor optimism regarding the company's efforts to expand its customer base.
stocktwits
7.5
06-17stocktwits
Hims & Hers Partners with Novo Nordisk, Boosting Stock Momentum
  • Growth Through Partnership: Novo Nordisk announced on March 9 that it will sell its blockbuster drugs Wegovy and Ozempic through Hims & Hers, with Barclays noting improved customer momentum, indicating a positive impact from the collaboration.
  • Price Target Increase: Barclays raised its price target for Hims & Hers from $29 to $39, implying a 21% upside from the last closing price, reflecting increased confidence in the company's future growth trajectory.
  • Revenue Acceleration Expectations: Revenue and EBITDA for Hims & Hers are expected to significantly accelerate in the second half of 2026 due to strong demand for weight-loss products and contributions from other business lines, further solidifying its market position.
  • Market Sentiment Rebound: Retail sentiment for Hims & Hers improved from 'bullish' to 'extremely bullish', with message activity rising over 120% in the past week, indicating investor optimism regarding the company's outlook.
stocktwits
8.5
06-17stocktwits
Hims & Hers Faces Key Regulatory Meeting on Peptides
  • Regulatory Meeting Impact: The Pharmacy Compounding Advisory Committee is set to meet on July 23-24 to decide on adding seven peptides to the FDA's 503A Bulk List, a move that could serve as a catalyst for Hims' growth prospects beyond 2027.
  • Market Performance Recovery: HIMS shares have surged over 20% recently, trading close to $31.8, breaking through the $30 resistance level from April, indicating optimistic market sentiment regarding future growth.
  • Potential Revenue Expectations: FirstWave Fund CEO Jonah Lupton stated that if Hims captures 4% to 5% of the GLP and non-GLP peptide markets, annual revenues could reach between $10 billion and $19 billion by 2030, significantly enhancing the company's market position.
  • Investor Focus: Despite the long-term opportunities presented by peptides, Leerink noted that investor attention is likely to remain on Hims' near-term growth and profitability trends in the GLP-1 business, especially following the company's recent acquisition of Eucalyptus, which has expanded its operations across multiple countries.
stocktwits
8.5
06-16stocktwits
Hims' Peptide Market Outlook for the Next Decade
  • Massive Market Potential: Lupton projects that the global peptide market could generate between $250 billion and $380 billion in annual revenue by 2030, and if Hims captures 4%-5% market share, peptide revenue could reach $10 billion to $19 billion, indicating significant growth opportunities in this sector.
  • Stock Price Surge: Shares of Hims & Hers Health, Inc. (HIMS) jumped over 12% on Monday to close at $30.17, marking the best performance in two months, reflecting growing market optimism surrounding peptide products.
  • Regulatory Support: Canaccord Genuity reiterated a ‘Buy’ rating and a $32 price target for Hims, suggesting that peptides could emerge as a long-term growth driver, with FDA reviews potentially shifting demand from unregulated channels to mainstream healthcare platforms.
  • Strategic Expansion: Hims has acquired a California-based peptide manufacturing facility to bolster its domestic supply chain and has expanded its vertically-integrated healthcare platform, demonstrating a strategic focus on metabolic health and cognitive performance, thereby strengthening its position in international markets.
NASDAQ.COM
2.0
06-16NASDAQ.COM
Regentis Soars After Withdrawing US Listing Application
  • Regentis Stock Surge: Regentis Biomaterials Ltd. (RGNT) saw its shares soar over 500% to close at $9.40 after withdrawing its Form F-1 registration with the SEC, indicating strong market confidence in its strategic decision.
  • GelrinC Product Development: The company's lead product, GelrinC, has received CE Mark approval in Europe, with plans to initiate surgeon training in Q3 2026, which is expected to enhance its market readiness and competitive positioning.
  • Cuprina FDA Approval: Cuprina Holdings (CUPR) received FDA clearance for its MEDIFLY maggots used in wound debridement therapy, leading to a stock increase of over 100%, reflecting its innovative potential and market demand in the medical field.
  • Intellia Positive Results: Intellia Therapeutics (NTLA) jumped over 20% following positive phase 3 results for its hereditary angioedema treatment, with plans for a BLA submission targeting FDA approval in the first half of 2027, showcasing its strong prospects in the biopharmaceutical sector.
Yahoo Finance
8.5
06-16Yahoo Finance
Hims & Hers Stock Surges 12.49% Amid Obesity Market Optimism
  • Stock Surge: Hims & Hers saw its stock price rise by 12.49% on Monday, closing at $30.17 per share, reflecting investor optimism regarding the company's growth prospects in the obesity market, indicating strong market confidence in its business model.
  • Obesity Treatment Demand: Chief Medical Officer Craig Primack highlighted that approximately 64% of UK adults are overweight or living with obesity, and NHS specialist weight management services are overwhelmed, with waiting lists closed in multiple regions, illustrating the inability of traditional healthcare systems to meet the surging demand for obesity treatment.
  • Integrated Treatment Solutions: Hims & Hers offers FDA-approved obesity and weight loss treatments, Wegovy and Ozempic, and aims to enhance treatment outcomes and patient satisfaction by integrating medication, nutritional coaching, and clinical support, effectively removing friction in the treatment process.
  • Market Opportunity: Primack emphasized that closing the gap between the obesity epidemic and the capacity of traditional care systems requires clinical rigor and sustained support, positioning Hims & Hers to capture a larger market share and influence in the future.
Wall Street analysts forecast HIMS stock price to rise
12 Analyst Rating
Wall Street analysts forecast HIMS stock price to rise
3 Buy
6 Hold
3 Sell
Hold
Current: 0.000
sliders
Low
16.50
Averages
32.95
High
60.00
Current: 0.000
sliders
Low
16.50
Averages
32.95
High
60.00
Barclays
Overweight
maintain
$29 -> $39
AI Analysis
2026-06-17
New
Reason
Barclays
Price Target
$29 -> $39
AI Analysis
2026-06-17
New
maintain
Overweight
Reason
Barclays raised the firm's price target on Hims & Hers (HIMS) to $39 from $29 and keeps an Overweight rating on the shares. A combination of weight loss and other more moderate contributors are driving a significant acceleration of revenues and EBITDA in the second half of 2026, the firm says. With shares flat year-to-date, Barclays sees an opportunity for the shares to break out as investors get more visibility on the ramp in the back half. The firm's proprietary data points to a clear inflection post-Novo Nordisk (NVO), Barclays says, highlighting that its alternative data has started to show improvement in the time since the partnership was announced on March 9.
BofA
Allen Lutz
Neutral
downgrade
$28 -> $25
2026-05-26
Reason
BofA
Allen Lutz
Price Target
$28 -> $25
2026-05-26
downgrade
Neutral
Reason
BofA analyst Allen Lutz lowered the firm's price target on Hims & Hers to $25 from $28 and keeps a Neutral rating on the shares. 2026 revenue guidance requires a significant GLP-1 ramp in the second half of the year and does not contemplate potential pricing pressure around the subscription fee, says the analyst, who lowered the firm's target multiple based on risks to the full year guide.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for HIMS
Unlock Now

Valuation Metrics

The current forward P/E ratio for Hims & Hers Health Inc (HIMS.N) is 58.82, compared to its 5-year average forward P/E of 11.92. For a more detailed relative valuation and DCF analysis to assess Hims & Hers Health Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
11.92
Current PE
58.82
Overvalued PE
69.36
Undervalued PE
-45.53

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
12.98
Current EV/EBITDA
-32.07
Overvalued EV/EBITDA
46.39
Undervalued EV/EBITDA
-20.43

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
2.77
Current PS
1.84
Overvalued PS
4.15
Undervalued PS
1.40

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

stocks that will explode in next 30 days
Intellectia · 640 candidates
Relative Vol: >= 1.50Moving Average Relationship: PriceAboveMA5, PriceAboveMA20Month Price Change Pct: >= $0.00One Month Rise Prob: >= 70One Month Predict Return: >= 0.0%
Ticker
Name
Market Cap$
top bottom
PRCH logo
PRCH
Porch Group Inc
1.23B
ROMA logo
ROMA
Roma Green Finance Ltd
396.70M
MCBS logo
MCBS
Metrocity Bankshares Inc
921.13M
UA logo
UA
Under Armour Inc
2.59B
INNV logo
INNV
InnovAge Holding Corp
1.08B
DOCN logo
DOCN
DigitalOcean Holdings Inc
15.94B
how to find fast rising U.S. stocks daily.
Intellectia · 37 candidates
Market Cap: >= 500.00MRegion: USPrice: $3.00 - $150.00Volume: >= 1,000,000Price Change Pct: >= $5.00List Exchange: XNYS, XNAS, XASE
Ticker
Name
Market Cap$
top bottom
MXL logo
MXL
Maxlinear Inc
3.07B
POET logo
POET
POET Technologies Inc
1.79B
OGN logo
OGN
Organon & Co
2.24B
INTC logo
INTC
Intel Corp
334.79B
INDI logo
INDI
indie Semiconductor Inc
777.25M
EOSE logo
EOSE
Eos Energy Enterprises Inc
2.35B
Day trading stocks
Intellectia · 26 candidates
Region: USPrice: $5.00 - $80.00Price Change Pct: >= $5.00Relative Vol: >= 2List Exchange: XNYS, XNAS, XASEMonthly Average Dollar Volume: >= 2,000,000
Ticker
Name
Market Cap$
top bottom
GFS logo
GFS
GlobalFoundries Inc
32.26B
UMC logo
UMC
United Microelectronics Corp
31.75B
SIRI logo
SIRI
Sirius XM Holdings Inc
9.16B
HIMS logo
HIMS
Hims & Hers Health Inc
7.07B
LEGN logo
LEGN
Legend Biotech Corp
4.64B
BB logo
BB
BlackBerry Ltd
3.23B
can you find one that is favorable
Intellectia · 63 candidates
Price: $5.00 - $50.00Volume: >= 1,000,000Rsi Category: moderate, overboughtPrice Change Pct: $3.00 - $15.00Relative Vol: >= 1.50List Exchange: XNYS, XNAS, XASE
Ticker
Name
Market Cap$
top bottom
SMR logo
SMR
Nuscale Power Corp
4.34B
HIMS logo
HIMS
Hims & Hers Health Inc
6.57B
IONQ logo
IONQ
IONQ Inc
16.90B
NCLH logo
NCLH
Norwegian Cruise Line Holdings Ltd
9.56B
COMP logo
COMP
Compass Inc
6.07B
HTZ logo
HTZ
Hertz Global Holdings Inc
2.34B
Any sector or business
Intellectia · 24 candidates
Market Cap: >= 1000.00MPrice: >= $5.00Price Change Pct: >= $5.00Monthly Average Dollar Volume: >= 1,000,000News Driver: Positive
Ticker
Name
Market Cap$
top bottom
NN logo
NN
NextNav Inc
2.92B
NVTS logo
NVTS
Navitas Semiconductor Corp
2.85B
SMMT logo
SMMT
Summit Therapeutics Inc
18.95B
RUM logo
RUM
Rumble Inc
2.78B
IRDM logo
IRDM
Iridium Communications Inc
4.59B
LUNR logo
LUNR
Intuitive Machines Inc
5.91B
which stocks I focus for day trading
Intellectia · 47 candidates
Market Cap: >= 2.00BRegion: USPrice: $10.00 - $70.00Price Change Pct: $4.00 - $18.00Relative Vol: >= 1.80List Exchange: XNYS, XNAS, XASEMonthly Average Dollar Volume: >= 3,000,000
Ticker
Name
Market Cap$
top bottom
PL logo
PL
Planet Labs PBC
11.91B
SMMT logo
SMMT
Summit Therapeutics Inc
16.39B
IRDM logo
IRDM
Iridium Communications Inc
4.02B
LUNR logo
LUNR
Intuitive Machines Inc
5.18B
SGML logo
SGML
Sigma Lithium Corp
2.03B
HIMS logo
HIMS
Hims & Hers Health Inc
5.54B
What is a good stock for day trade today
Intellectia · 194 candidates
Market Cap: >= 500.00MPrice: $5.00 - $100.00Price Change Pct: $3.00 - $15.00Relative Vol: >= 2Beta: HighRiskList Exchange: XNYS, XNAS, XASE
Ticker
Name
Market Cap$
top bottom
INTC logo
INTC
Intel Corp
206.50B
ONDS logo
ONDS
Ondas Inc
3.78B
NU logo
NU
Nu Holdings Ltd
65.60B
NIO logo
NIO
NIO Inc
13.68B
CDE logo
CDE
Coeur Mining, Inc
10.59B
U logo
U
Unity Software Inc
8.96B
list top 10 stocks with bullish momentum
Intellectia · 88 candidates
Market Cap: >= 2.00BRegion: USRsi Category: moderateList Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA20, PriceAboveMA200Month Price Change Pct: >= $10.00
Ticker
Name
Market Cap$
top bottom
AAOI logo
AAOI
Applied Optoelectronics Inc
8.89B
BW logo
BW
Babcock & Wilcox Enterprises Inc
2.11B
AHG logo
AHG
Akso Health Group
2.03B
AMPX logo
AMPX
Amprius Technologies Inc
2.46B
DNTH logo
DNTH
Dianthus Therapeutics Inc
4.02B
CVI logo
CVI
CVR Energy Inc
3.29B
create a stock picker with 1000 to spend
Intellectia · 44 candidates
Market Cap: 1000.00M - 15.00BPrice: $10.00 - $40.00Rsi Category: moderateList Exchange: XNYS, XNAS, XASEMonth Price Change Pct: $10.00 - $35.00One Week Rise Prob: 0 - 100Monthly Average Dollar Volume: >= 1,000,000
Ticker
Name
Market Cap$
top bottom
BTU logo
BTU
Peabody Energy Corp
4.65B
PLSE logo
PLSE
Pulse Biosciences Inc
1.45B
PUMP logo
PUMP
ProPetro Holding Corp
1.81B
TEN logo
TEN
Tsakos Energy Navigation Ltd
1.19B
CRK logo
CRK
Comstock Resources Inc
6.27B
VECO logo
VECO
Veeco Instruments Inc
2.08B
strong short term stocks
Intellectia · 19 candidates
Market Cap: >= 5.00BRsi Category: moderateList Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA20Week Price Change Pct: >= $3.00Month Price Change Pct: >= $10.00
Ticker
Name
Market Cap$
top bottom
CZR logo
CZR
Caesars Entertainment Inc
5.71B
HIMS logo
HIMS
Hims & Hers Health Inc
5.65B
DELL logo
DELL
Dell Technologies Inc
100.48B
PBF logo
PBF
PBF Energy Inc
5.09B
CGON logo
CGON
CG Oncology Inc
5.43B
TERN logo
TERN
Terns Pharmaceuticals Inc
5.06B

Whales Holding HIMS

B
BIT Capital GmbH
Holding
HIMS
+32.68%
3M Return
C
Cantor Fitzgerald Asset Management
Holding
HIMS
+27.41%
3M Return
C
Clear Street LLC
Holding
HIMS
+23.97%
3M Return
D
Divisadero Street Capital Management, LP
Holding
HIMS
+21.70%
3M Return
S
Summit Trail Advisors, LLC
Holding
HIMS
+16.03%
3M Return
T
The State of Michigan Retirement Systems
Holding
HIMS
+14.70%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Hims & Hers Health Inc (HIMS) stock price today?

The current price of HIMS is 35.47 USD — it has increased 11.23

What is Hims & Hers Health Inc (HIMS)'s business?

Hims & Hers Health, Inc. operates as a consumer-first platform, which helps customers to fulfill their health and wellness needs. Its platform includes access to a provider network, a clinically focused electronic medical record system, digital prescriptions, cloud-enabled pharmacy fulfillment, and personalization capabilities. Its digital platform enables access to treatments for a range of conditions, including primarily those related to sexual health, hair loss, hormone health, weight loss, dermatology, and mental health, as well as services such as comprehensive laboratory testing. It connects patients to licensed healthcare professionals who can prescribe medications when appropriate and prescriptions are fulfilled online through licensed pharmacies. It also offers access to a range of health and wellness products designed to meet individual needs, which can include curated prescription and non-prescription products.

What is the price predicton of HIMS Stock?

Wall Street analysts forecast HIMS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HIMS is32.95 USD with a low forecast of 16.50 USD and a high forecast of 60.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Hims & Hers Health Inc (HIMS)'s revenue for the last quarter?

Hims & Hers Health Inc revenue for the last quarter amounts to 608.10M USD, increased 3.77

What is Hims & Hers Health Inc (HIMS)'s earnings per share (EPS) for the last quarter?

Hims & Hers Health Inc. EPS for the last quarter amounts to -0.40 USD, decreased -300.00

How many employees does Hims & Hers Health Inc (HIMS). have?

Hims & Hers Health Inc (HIMS) has 2442 emplpoyees as of June 22 2026.

What is Hims & Hers Health Inc (HIMS) market cap?

Today HIMS has the market capitalization of 8.21B USD.